V06-05 TRANSPERINEAL LASER ABLATION FOR BENIGN PROSTATIC HYPERPLASIA (BPH): FEASIBILITY AND SAFETY

Abstract

You have accessJournal of UrologyBPH & Infection & Imaging (V06)1 Sep 2021V06-05 TRANSPERINEAL LASER ABLATION FOR BENIGN PROSTATIC HYPERPLASIA (BPH): FEASIBILITY AND SAFETY Fernando Bianco, Alberto Lopez-Prieto, Eusebio Luna, Avila Luis, Edward Gheiler, Ariel Kaufman, and David Cohen Fernando BiancoFernando Bianco More articles by this author , Alberto Lopez-PrietoAlberto Lopez-Prieto More articles by this author , Eusebio LunaEusebio Luna More articles by this author , Avila LuisAvila Luis More articles by this author , Edward GheilerEdward Gheiler More articles by this author , Ariel KaufmanAriel Kaufman More articles by this author , and David CohenDavid Cohen More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000002021.05AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: BPH affects millions of men in the US. TURP or greenlight laser ablation are effective but require general anesthesia. They impose bladder neck destruction resulting in retrograde ejaculation. Ejaculation preservation is a premise for newer approaches – Urolift, REZUM. Their intraurethral nature triggers irritative symptoms. Herein, we present the feasibility and safety results from a novel approach transperineal laser ablation (TPLA) under local anesthesia in the office setting. METHODS: URN20-014, a Phase I trial, aims to evaluate feasibility, safety as well as 3-, 6- and 12-months outcomes for TPLA. The trial design contemplated 20 subjects. All subjects had complete lower urinary tract evaluation with pressure flow studies, IPSS and SHIM scores and ultrasonographic prostate volume measurements. Renal function biomarkers as well as PSA were collected. The protocol called for 2-4 Echolaser4 (Elesta Els, Italy) TPLA applications in the prostate under ultrasound guidance aided by the ELS tracing system. The procedure is shown on the VIDEO. RESULTS: Results: TPLA was performed and completed in all participants. The median room and ablation times were 20 minutes and 9 minutes, respectively. Median pain score was 3 (range 1-5). 11/20 patients were discharged without catheters. At 30 days, there was a 4-point median improvement in IPSS scores. Hematospermia (15/20) was common as well. There were no ER visits. CONCLUSIONS: TPLA seems feasible and safe. Functional outcomes are pending. Source of Funding: None © 2021 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 206Issue Supplement 3September 2021Page: e450-e450 Advertisement Copyright & Permissions© 2021 by American Urological Association Education and Research, Inc.MetricsAuthor Information Fernando Bianco More articles by this author Alberto Lopez-Prieto More articles by this author Eusebio Luna More articles by this author Avila Luis More articles by this author Edward Gheiler More articles by this author Ariel Kaufman More articles by this author David Cohen More articles by this author Expand All Advertisement PDF downloadLoading ...